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The field of pediatric oncology has assimilated the overlapping concepts of survivorship and late ef-
fects, recognizing that a key objective of treatment is 
to increase the number of young people surviving while 
minimizing long-term disadvantage and ill health (1). 
This concept is evolving in the care of young adults with 
cancer, partly spurred on by the growing awareness of 
patients and practitioners of the potential of loss of fer-
tility and the potential to preserve it (2). Implicit in this 
is the need for an accurate assessment of the female re-
productive function that ideally would estimate both 
immediate and long-term fertility, and the remaining 
reproductive lifespan. This also has relevance to wider 
aspects of women’s health, most clearly established for 
bone health, but likely also to have implications for car-
diovascular and cognitive function, and indeed overall 
lifespan (3).
The dynamic nature of ovarian function means that 
there are large variations in conventional markers of 
ovarian activity, notably estradiol and follicle stimulating 
hormone. These largely reflect the latest stages of follicle 
growth in relation to ovulation, and it has really been the 
advent of the measurement of anti-Müllerian hormone 
(AMH) that has given us the opportunity to explore the 
activity of the ovary in terms of its smaller follicles (4). 
Measurement of AMH has become routine in assisted 
reproduction as a predictor of the ovarian response to 
stimulation, but its potential role in diagnosing—or in-
deed predicting—menopause in healthy women and 
premature ovarian insufficiency (POI) in patients diag-
nosed and treated for cancer have also been recognized. 
It is also clear that AMH is of no value as a predictor of 
short-term fertility (5). In women with cancer, AMH falls 
markedly during chemotherapy, with variable recovery 
thereafter depending on the degree of gonadotoxicity 
of the treatment administered (6). This has been dem-
onstrated in prepubertal girls, in young adults, and in 
older premenopausal women, but generally in relatively 
small studies, particularly when prospective and mostly 
with less than a 5-year follow-up. The question of the 
longer-term function of the chemotherapy-exposed 
ovary therefore remains very uncertain, and it is this that 
Su and colleagues have investigated in a paper in the cur-
rent edition of the Journal of Clinical Endocrinology and 
Metabolism (7). The study recruited women who had 
been diagnosed with cancer from the ages of 18 to 39 
who were on the registries of 2 US states or were known 
to participating research centers. A total of 763 women 
participated and provided blood samples in the form of 
dried blood spots up to 15 years from diagnosis, with in-
dividual women contributing up to 4 samples (although 
approximately a third contributed only 1); AMH con-
centration was calculated as a serum-equivalent value. 
Importantly, the diagnosis and details of treatment were 
ascertained by physicians rather than self-reported. 
The treatment exposure was stratified into 3 groups 
defined as low, moderate, or high gonadotoxicity. The 
low group contains treatments that essentially were not 
gonadotoxic, including surgery only (excluding hyster-
ectomy and/or oophorectomy), endocrine therapy only, 
radioiodine treatment, and cervical trachelectomy. The 
high gonadotoxic treatments included any exposure to 
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pelvic radiation, stem cell or bone marrow transplant, or 
cyclophosphamide equivalent dose (CED) of >7 grams/
m2. All other patients were stratified into the moderate 
gonadotoxicity group, which although included patients 
exposed to alkylating agent chemotherapy below CED 
7 grams/m2 and indeed any other chemotherapy, ra-
ther surprisingly also included patients who had a hys-
terectomy or unilateral oophorectomy. Targeted agents 
were also included in the “moderate” risk group, des-
pite the near-complete absence of evidence regarding 
their gonadotoxicity. The authors highlight the diffi-
culties and limitations of their classification in relation 
to overlapping AMH results, but this seems inevitable 
given that this classification was the starting point of 
their analysis, rather than determining a degree of re-
duced ovarian function, which could then be related to 
particular therapies.
It is noteworthy that the participants were predomin-
antly Caucasian and well-educated. Approximately half 
had had either breast cancer or lymphoma, with some 
diagnoses, notably leukemia, being underrepresented and 
thyroid cancer being overrepresented. The authors used 
an innovative design of a combination of longitudinal 
and cross-sectional analysis, with a functional principal 
components analysis to allow for the irregular spacing 
and sparseness of the data. The key findings were that 
in all groups there was an increase in AMH levels in the 
initial 2  years after treatment, although the values re-
mained low. Thereafter, there was a fairly long-lasting 
plateau, followed by a decline to very low levels. The 
high gonadotoxicity group differed somewhat from the 
other 2 groups, with a shorter duration of postrecovery 
plateau and, in general, lower AMH levels throughout. 
The findings were not related to a diagnosis of POI or a 
self-reported final menstrual period, nor were any of the 
details of the treatment received analyzed. These results, 
therefore, are largely confirmatory of previous smaller 
studies, with the key advances being the large number of 
participants, the very long time since diagnosis in some 
patients, and, particularly, the novel use of self-collected 
dried blood spots. The wide variation in the number 
of primordial follicles within the ovaries of women at 
similar ages may be a major factor in contributing to the 
overlapping results of the different risk groups. The ab-
sence of a pretreatment sample, which we and others have 
found to be an important predictor of postchemotherapy 
ovarian function (8), is an important limitation.
The data set that the authors have collected contains a 
wealth of information on treatment and subject variables, 
and it is likely that further analyses will provide substantially 
more detailed information. The use of dried blood spots also 
deserves wider exploration and validation in this and other 
contexts, in particular in relation to the developing use of 
AMH in the prediction of imminent menopause (9). There is 
still some way to go, therefore, before what the individual pa-
tient needs (ie, an accurate prediction of future reproductive 
function and lifespan) can be provided, but this paper pro-
vides a significant advance in the use of AMH as a valuable 
biomarker in the field of postcancer ovarian function and, by 
broader implication, in women’s long-term health after cancer.
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